Key Points
- Hanlin Gao sold 943 Fulgent shares on Nov. 28 at an average price of $29.57 for $27,884.51, reducing his position by 0.10% to 953,965 shares valued at about $28.21M; he also sold 535 shares on Nov. 24 and 1,063 on Sept. 3.
- Fulgent beat estimates in its Nov. 7 quarter with $0.14 EPS (vs. -$0.22 expected) and $84.07M revenue, but the company still reports a negative net margin (16.83%) and negative ROE, while management guided FY2025 EPS to $0.30 and analysts forecast -0.85 for the current fiscal year.
- Shares opened at $28.52 (down ~3.6%), market cap is about $881.6M with a 12‑month range of $14.57–$31.04, and Wall Street views are mixed—an average "Hold" rating with an average target near $32 (two Buys, one Hold, one Sell).
Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report) insider Hanlin Gao sold 943 shares of Fulgent Genetics stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $29.57, for a total transaction of $27,884.51. Following the transaction, the insider directly owned 953,965 shares in the company, valued at $28,208,745.05. The trade was a 0.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Hanlin Gao also recently made the following trade(s):
- On Monday, November 24th, Hanlin Gao sold 535 shares of Fulgent Genetics stock. The shares were sold at an average price of $30.47, for a total transaction of $16,301.45.
- On Wednesday, September 3rd, Hanlin Gao sold 1,063 shares of Fulgent Genetics stock. The stock was sold at an average price of $22.03, for a total transaction of $23,417.89.
Fulgent Genetics Stock Down 3.6%
Shares of NASDAQ FLGT opened at $28.52 on Tuesday. Fulgent Genetics, Inc. has a twelve month low of $14.57 and a twelve month high of $31.04. The stock has a market cap of $881.61 million, a price-to-earnings ratio of -17.18 and a beta of 0.92. The company's fifty day moving average is $24.98 and its 200-day moving average is $22.06.
Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last released its quarterly earnings data on Friday, November 7th. The company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.36. The business had revenue of $84.07 million during the quarter, compared to analysts' expectations of $81.43 million. Fulgent Genetics had a negative net margin of 16.83% and a negative return on equity of 2.26%. Fulgent Genetics has set its FY 2025 guidance at 0.300-0.300 EPS. On average, research analysts anticipate that Fulgent Genetics, Inc. will post -0.85 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms have recently commented on FLGT. Raymond James Financial reaffirmed an "outperform" rating and set a $36.00 price target on shares of Fulgent Genetics in a research report on Friday, November 14th. Weiss Ratings restated a "sell (d-)" rating on shares of Fulgent Genetics in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Fulgent Genetics from a "hold" rating to a "buy" rating in a report on Saturday, November 15th. UBS Group raised shares of Fulgent Genetics from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $20.00 to $30.00 in a research report on Tuesday, August 5th. Finally, Piper Sandler boosted their price objective on shares of Fulgent Genetics from $21.00 to $30.00 and gave the company a "neutral" rating in a research report on Tuesday, November 11th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $32.00.
Check Out Our Latest Research Report on FLGT
Hedge Funds Weigh In On Fulgent Genetics
A number of institutional investors have recently added to or reduced their stakes in FLGT. Millennium Management LLC raised its position in Fulgent Genetics by 28.6% during the first quarter. Millennium Management LLC now owns 1,969,433 shares of the company's stock worth $33,283,000 after acquiring an additional 437,632 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Fulgent Genetics by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,179,254 shares of the company's stock worth $26,651,000 after purchasing an additional 13,295 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Fulgent Genetics by 38.7% in the 2nd quarter. Acadian Asset Management LLC now owns 1,117,917 shares of the company's stock valued at $22,208,000 after purchasing an additional 311,976 shares during the period. Geode Capital Management LLC lifted its stake in Fulgent Genetics by 1.6% in the 2nd quarter. Geode Capital Management LLC now owns 513,343 shares of the company's stock valued at $10,207,000 after purchasing an additional 8,105 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Fulgent Genetics by 22.2% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 305,180 shares of the company's stock worth $6,067,000 after purchasing an additional 55,521 shares during the period. 48.06% of the stock is currently owned by institutional investors and hedge funds.
Fulgent Genetics Company Profile
(
Get Free Report)
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
